Spectral AI (Spectral AI) Net Margin % : -50.66% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Spectral AI Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Spectral AI's Net Income for the three months ended in Mar. 2024 was $-3.21 Mil. Spectral AI's Revenue for the three months ended in Mar. 2024 was $6.33 Mil. Therefore, Spectral AI's net margin for the quarter that ended in Mar. 2024 was -50.66%.

The historical rank and industry rank for Spectral AI's Net Margin % or its related term are showing as below:

MDAI' s Net Margin % Range Over the Past 10 Years
Min: -115.5 Med: -26.17 Max: -11.48
Current: -115.46

MDAI's Net Margin % is ranked worse than
78.04% of 815 companies
in the Medical Devices & Instruments industry
Industry Median: -1.64 vs MDAI: -115.46

Spectral AI Net Margin % Historical Data

The historical data trend for Spectral AI's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectral AI Net Margin % Chart

Spectral AI Annual Data

Trend

Dec21

Dec22

Dec23

Net Margin %

-26.17

-11.48

-115.50

Spectral AI Quarterly Data
	Dec21	Mar22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Net Margin %	Get a 7-Day Free Trial			-28.53	-71.07	-308.98	-67.07	-50.66

Competitive Comparison of Spectral AI's Net Margin %

For the Medical Devices subindustry, Spectral AI's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spectral AI's Net Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Spectral AI's Net Margin % distribution charts can be found below:

* The bar in red indicates where Spectral AI's Net Margin % falls into.

Spectral AI Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Spectral AI's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-20.854	/	18.056
	=	-115.50 %

Spectral AI's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin	=	Net Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-3.205	/	6.326
	=	-50.66 %

Spectral AI (NAS:MDAI) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Spectral AI Net Margin % Related Terms

Thank you for viewing the detailed overview of Spectral AI's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Spectral AI (Spectral AI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Spectral AI Inc (NAS:MDAI) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2515 McKinney Avenue, Suite 1000, Dallas, TX, USA, 75201

Website

https://www.spectralmd.com

Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely and informed decision regarding the treatment of the patient's wound.

Executives

John Michael Dimaio	10 percent owner	6125 LUTHER LANE, DALLAS TX 75225
Michael Patrick Murphy	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Els 1960 Family, L.p.	10 percent owner	2323 VICTORY AVE., SUITE. 700, DALLAS TX 75219
Richard John Cotton	director	RUE DU VILLAGE 4, CHAMPERY V8 1874
Mellish Martin C.b.	director	13 BERRILL FARMS LN, HANOVER NH 03755
Jeffrey Edward Thatcher	officer: Chief Scientist	6659 ESCONDIDO ST, IRVING TX 75039
Nils Windler	officer: Chief Financial Officer	8602 NAPA LANDING, SAN ANTONIO TX 78015
Wensheng Fan	director, officer: CHIEF EXECUTIVE OFFICER	3320 SPRING MOUNTAIN DRIVE, PLANO TX 75025
Vincent S. Capone	officer: GENERAL COUNSEL	1620 GRASSHOPPER LANE, LOWER GWYNEDD PA 19002
Nikolaos Pagoulatos	officer: CHIEF OPERATING OFFICER	5122 IROQUOIS DR, FRISCO TX 75034
Xiaojia Cynthia Cai	director	10 CELESTIAL WAY, NEWARK DE 19711
Heather Bellini	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Edmonds Franklin S. Jr.	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Rosecliff Acquisition Sponsor I Llc	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Erich Spangenberg	10 percent owner	73 595 EL PASEO, SUITE 2204, PALM DESERT CA 92260